

CESIÓN

- (1) LEE, Sibeum
- (2) JEON, Soomin
- (3) LEE, Dongho
- (4) LEE, Youngeun
- (5) PARK, Yejin

con domicilio en:

- (1) 9 Dongbaek 3-ro 60beon-gil Giheung-gu, Yongin-si Gyeonggi-do 17009 (KR)
- (2) 2134-301, Geumgang Penterium Central Park IV, 45 Dongtansunhwan-daero 20-gil Hwaseong-si Gyeonggi-do 18484 (KR)
- (3) 305-3101, 56 Giheungyeok-ro 58beon-gil Giheung-gu, Yongin-si Gyeonggi-do 17066 (KR)
- (4) 3103-2201, 19 Beopjo-ro 150beon-gil Yeongtong-gu, Suwon-si Gyeonggi-do 16512 (KR)
- (5) A-809, 551-16 Dongtan-daero Hwaseong-si Gyeonggi-do 18478 (KR)

declaran bajo juramento ser únicos y verdaderos inventores de la invención de la solicitud internacional

PCT/IB2024/050870

declaran así mismo que ceden y transfieren sin limitación todos los derechos inherentes a dicha invención a favor de:

1. **ONCONIC THERAPEUTICS INC.**
2. **JEIL PHARMACEUTICAL CO., LTD.**

constituídas y existentes de conformidad con las leyes de:

Core del Sur

con domicilio en:

1. 11F, 12 Teheran-ro 26-gil Gangnam-gu Seoul 06236 (KR)
2. 343, Sapyeong-daero Seocho-Gu Seoul 06543 (KR)

Las citadas Compañías quedan facultadas para solicitar en su nombre la patente correspondiente en la República de Colombia.

En testimonio de lo anterior, se suscribe este documento en

ASSIGNMENT

- (1) LEE, Sibeum
- (2) JEON, Soomin
- (3) LEE, Dongho
- (4) LEE, Youngeun
- (5) PARK, Yejin

domiciled at:

- (1) 9 Dongbaek 3-ro 60beon-gil Giheung-gu, Yongin-si Gyeonggi-do 17009 (KR)
- (2) 2134-301, Geumgang Penterium Central Park IV, 45 Dongtansunhwan-daero 20-gil Hwaseong-si Gyeonggi-do 18484 (KR)
- (3) 305-3101, 56 Giheungyeok-ro 58beon-gil Giheung-gu, Yongin-si Gyeonggi-do 17066 (KR)
- (4) 3103-2201, 19 Beopjo-ro 150beon-gil Yeongtong-gu, Suwon-si Gyeonggi-do 16512 (KR)
- (5) A-809, 551-16 Dongtan-daero Hwaseong-si Gyeonggi-do 18478 (KR)

declare under oath that they are sole and true inventors of the invention of international application

PCT/IB2024/05087

the inventors further declare they assign and transfer without limitations all rights inherent to said invention in favor of:

1. **ONCONIC THERAPEUTICS INC.**
2. **JEIL PHARMACEUTICAL CO., LTD.**

corporations incorporated and existing under the laws of:

South Korea

domiciled at:

1. 11F, 12 Teheran-ro 26-gil Gangnam-gu Seoul 06236 (KR)
2. 343, Sapyeong-daero Seocho-Gu Seoul 06543 (KR)

The above-mentioned companies are authorized to apply, in their name, for the corresponding patent in the Republic of Colombia.

In witness whereof, this document is signed in

CAVELIER

ABOGADOS

Ciudad | City **Seoul, Republic of Korea**

Fecha | Date **July 17, 2025**

Por | By **LEE, Sibeum**

Firma | Signature

Lee. Sibeum

Ciudad | City **Seoul, Republic of Korea**

Fecha | Date **July 17, 2025**

Por | By **JEON, Soomin**

Firma | Signature

Jeon. Soomin

Ciudad | City **Seoul, Republic of Korea**

Fecha | Date **July 17, 2025**

Por | By **LEE, Dongho**

Firma | Signature

Lee, Dongho

Ciudad | City **Seoul, Republic of Korea**

Fecha | Date **July 17, 2025**

Por | By **LEE, Youngeun**

Firma | Signature

Lee. Youngeun

Ciudad | City **Seoul, Republic of Korea**

Fecha | Date **July 17, 2025**

Por | By **PARK, Yejin**

Firma | Signature

Park, Yejin